ABBY DOSSETT: Open Payments
NPI 1245814250 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$955 in 42 payments from 13 companies in 2025. Trend: 2023 $1,309 · 2024 $1,268 · 2025 $955
Food & beverage: $955
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $227 |
| Madrigal Pharmaceuticals | 5 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $139 |
| Gilead Sciences, Inc. | 4 | $99 |
| Lilly USA, LLC | 3 | $66 |
| QOL Medical, LLC | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Janssen Biotech, Inc. | 2 | $35 |
| GENZYME CORPORATION | 1 | $31 |
| Braintree Laboratories, Inc. | 1 | $24 |
Products named: REZDIFFRA, RINVOQ, ENTYVIO, DUPIXENT, OMVOH, Sucraid, CREON, MAVYRET.
Industry payments across IN — which companies pay providers there.
